Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to -$5.2 million.

  • Strata Critical Medical's Gains from Investment Securities fell 183745.82% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 132940.14%. This contributed to the annual value of $5.7 million for FY2024, which is 36743.53% up from last year.
  • Strata Critical Medical's Gains from Investment Securities amounted to -$5.2 million in Q3 2025, which was down 183745.82% from -$77000.0 recorded in Q2 2025.
  • Strata Critical Medical's 5-year Gains from Investment Securities high stood at $14.9 million for Q2 2021, and its period low was -$19.3 million during Q2 2022.
  • For the 5-year period, Strata Critical Medical's Gains from Investment Securities averaged around -$751842.1, with its median value being -$77000.0 (2025).
  • Per our database at Business Quant, Strata Critical Medical's Gains from Investment Securities tumbled by 334594.59% in 2022 and then surged by 36813.9% in 2024.
  • Over the past 5 years, Strata Critical Medical's Gains from Investment Securities (Quarter) stood at -$10.9 million in 2021, then soared by 81.81% to -$2.0 million in 2022, then soared by 185.58% to $1.7 million in 2023, then soared by 368.14% to $7.9 million in 2024, then plummeted by 165.35% to -$5.2 million in 2025.
  • Its last three reported values are -$5.2 million in Q3 2025, -$77000.0 for Q2 2025, and $4.3 million during Q1 2025.